Published in Arthritis Rheum on August 01, 1993
Pulmonary vasculitis. Proc Am Thorac Soc (2006) 2.54
Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res (2001) 2.18
Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): a Fc gamma RII-dependent process. Clin Exp Immunol (1994) 1.85
The diversity of perinuclear antineutrophil cytoplasmic antibodies (pANCA) antigens. Clin Exp Immunol (1995) 1.25
Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: characterization and clinical correlates. Clin Exp Immunol (1994) 1.12
Catalase and alpha-enolase: two novel granulocyte autoantigens in inflammatory bowel disease (IBD). Clin Exp Immunol (1998) 1.05
Anti-lactoferrin antibodies in systemic lupus erythematosus: isotypes and clinical correlates. Clin Rheumatol (2004) 0.97
Prevalence and clinical significance of antikeratin antibodies and other serological markers in Lithuanian patients with rheumatoid arthritis. Ann Rheum Dis (2001) 0.93
Specificities of anti-neutrophil autoantibodies in patients with rheumatoid arthritis (RA). Clin Exp Immunol (1997) 0.92
Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)? Clin Exp Immunol (1999) 0.90
NETs: the missing link between cell death and systemic autoimmune diseases? Front Immunol (2013) 0.89
B lymphocytopenia in rheumatoid arthritis is associated with the DRB1 shared epitope and increased acute phase response. Arthritis Res (2002) 0.84
Low Serum Alpha-Antitrypsin Associated with Anti-PR-3 ANCA in Autistic Children with GI Disease. Genomics Insights (2009) 0.82
Antineutrophil cytoplasmic antibodies in Bulgarian patients with rheumatoid arthritis: characterization and clinical associations. Rheumatol Int (2004) 0.77
Clinical utility of testing for antineutrophil cytoplasmic antibodies. Clin Diagn Lab Immunol (1999) 0.77
Amphipathic variable region heavy chain peptides derived from monoclonal human Wegener's anti-PR3 antibodies stimulate lymphocytes from patients with Wegener's granulomatosis and microscopic polyangiitis. Clin Exp Immunol (2001) 0.75
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum (1995) 26.94
Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum (1994) 14.16
Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis (1990) 5.49
Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med (1996) 4.18
The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum (2000) 4.10
Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol (1994) 3.50
Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum (1990) 3.37
Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. J Clin Invest (1989) 3.34
Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum (1992) 3.05
Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med (1994) 2.62
Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol (1992) 2.29
Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis (1992) 2.26
Association of autoantibodies to myeloperoxidase with different forms of vasculitis. Arthritis Rheum (1990) 2.24
Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med (2000) 2.19
Vitamin E status during dietary fish oil supplementation in rheumatoid arthritis. Arthritis Rheum (1990) 2.14
Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet (1990) 2.12
[Sjögren's disease]. Ned Tijdschr Geneeskd (1994) 2.00
The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med (2001) 1.89
Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): a Fc gamma RII-dependent process. Clin Exp Immunol (1994) 1.85
Antiproteinase 3- and antimyeloperoxidase-associated vasculitis. Kidney Int (2000) 1.81
Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum (1995) 1.80
Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. Kidney Int (1990) 1.77
IgM, IgA, and IgG rheumatoid factors in early rheumatoid arthritis predictive of radiological progression? Scand J Rheumatol (1995) 1.76
The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. Biochem Biophys Res Commun (1988) 1.76
Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum (2000) 1.74
Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide. J Rheumatol (1993) 1.71
Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 1. Relation to clinical parameters in 250 patients. J Neurol Sci (1983) 1.69
Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders. Clin Exp Immunol (1991) 1.69
Neutrophil activation in vitro and in vivo in Wegener's granulomatosis. Kidney Int (1994) 1.66
Antimyeloperoxidase-associated proliferative glomerulonephritis: an animal model. J Exp Med (1993) 1.63
Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol (1999) 1.62
Skin sensitivity to UVB irradiation in systemic lupus erythematosus is not related to the level of apoptosis induction in keratinocytes. Rheumatology (Oxford) (2005) 1.59
In vivo IgA coating of anaerobic bacteria in human faeces. Gut (1996) 1.55
Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol (1995) 1.53
Scl-86, a marker antigen for diffuse scleroderma. J Clin Invest (1985) 1.43
Co-trimoxazole and Wegener's granulomatosis: more than a coincidence? Nephrol Dial Transplant (1997) 1.43
Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology (1993) 1.41
Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol (2001) 1.41
Direct flow cytometry of anaerobic bacteria in human feces. Cytometry (1994) 1.41
[The role of perinuclear antineutrophil granulocytes cytoplasmic antibodies in the diagnosis of vasculitis and chronic inflammatory diseases]. Ned Tijdschr Geneeskd (1996) 1.40
No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Ann Rheum Dis (2000) 1.40
Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies. Ann Rheum Dis (1982) 1.39
Validity and reliability of joint indices. A longitudinal study in patients with recent onset rheumatoid arthritis. Br J Rheumatol (1993) 1.39
Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann Rheum Dis (2004) 1.38
Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim Biophys Acta (1991) 1.38
Leukocyte activation in sepsis; correlations with disease state and mortality. Intensive Care Med (2000) 1.38
Autoantibodies to myeloperoxidase aggravate mild anti-glomerular-basement-membrane-mediated glomerular injury in the rat. Am J Pathol (1996) 1.37
Increased frequency of B8/DR3 in scleroderma and association of the haplotype with impaired cellular immune response. Clin Exp Immunol (1981) 1.34
Cutaneous reactions to captopril. Predictive value of skin tests. Clin Allergy (1984) 1.34
Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol (1997) 1.34
The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol (1993) 1.33
Rapid automated enzyme immunoassay of serum amyloid A. Clin Chem (1994) 1.31
Monocyte activation in patients with Wegener's granulomatosis. Ann Rheum Dis (1999) 1.31
Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis (1995) 1.29
Systemic involvement and immunologic findings in patients presenting with Raynaud's phenomenon. Am J Med (1980) 1.28
Radiographic damage in large joints in early rheumatoid arthritis: relationship with radiographic damage in hands and feet, disease activity, and physical disability. Br J Rheumatol (1997) 1.27
Absence of cross-reactivity between captopril and enalapril. Lancet (1984) 1.24
Immune-complex glomerulopathy in patients treated with captopril. Lancet (1980) 1.23
B cell activity in systemic lupus erythematosus: depressed in vivo humoral immune response to a primary antigen (haemocyanin) and increased in vitro spontaneous immunoglobulin synthesis. Clin Exp Immunol (1983) 1.22
Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus (2006) 1.20
Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood (1995) 1.19
Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood (1994) 1.16
Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin Exp Immunol (1994) 1.15
Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis (2001) 1.14
C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol (1990) 1.14
Patients with systemic lupus erythematosus and Jaccoud's arthropathy: a clinical subset with an increased C reactive protein response? Ann Rheum Dis (1992) 1.13
Effects of fish oil supplementation in rheumatoid arthritis. Ann Rheum Dis (1990) 1.13
Serum markers of T cell activation in relapses of Wegener's granulomatosis. Clin Exp Immunol (1993) 1.13
Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity? Clin Exp Immunol (1992) 1.13
Lack of endothelial nitric oxide synthase aggravates murine accelerated anti-glomerular basement membrane glomerulonephritis. Am J Pathol (2000) 1.13
Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: characterization and clinical correlates. Clin Exp Immunol (1994) 1.12
HMGB1 in systemic lupus Erythematosus: Its role in cutaneous lesions development. Autoimmun Rev (2010) 1.12
HMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis. Autoimmun Rev (2012) 1.12
Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis. Kidney Int (1998) 1.11
Detection of autoantibodies against myeloid lysosomal enzymes: a useful adjunct to classification of patients with biopsy-proven necrotizing arteritis. Am J Med (1991) 1.11
Older versus younger onset rheumatoid arthritis: results at onset and after 2 years of a prospective followup study of early rheumatoid arthritis. J Rheumatol (1991) 1.10
Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis (2005) 1.09